Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer.

about

CIC-DUX4 Induces Small Round Cell Sarcomas Distinct from Ewing Sarcoma.How to Hit Mesenchymal Stromal Cells and Make the Tumor Microenvironment Immunostimulant Rather Than Immunosuppressive.

P2860

Q51061820-F34D6572-7085-4DD8-A31E-34491D86A7CB Q52668325-7E61DACF-2559-4355-873E-126649ADE364

P2860

Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer.

Item

http://www.wikidata.org/entity/Q40796265

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Phase I clinical trial of lena ...... patients with advanced cancer.

@en

type

Item

label

Phase I clinical trial of lena ...... patients with advanced cancer.

@en

prefLabel

Phase I clinical trial of lena ...... patients with advanced cancer.

@en

P1476

Phase I clinical trial of lena ...... patients with advanced cancer.

@en

P2093

David S Hong

http://www.w3.org/2001/XMLSchema#string

Eugenia Kakadiaris

http://www.w3.org/2001/XMLSchema#string

Gerald Falchook

http://www.w3.org/2001/XMLSchema#string

Jennifer J Wheler

http://www.w3.org/2001/XMLSchema#string

Rabih Said

http://www.w3.org/2001/XMLSchema#string

Ralph Zinner

http://www.w3.org/2001/XMLSchema#string

Sarina Piha-Paul

http://www.w3.org/2001/XMLSchema#string

Siqing Fu

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer.

Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer.

Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production.

Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma.

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.

Lenalidomide in solid tumors.

Bevacizumab: a review of its use in advanced cancer.

Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro.

P2888

s00280-016-3000-3

P304

1097-1102

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-016-3000-3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Razelle Kurzrock

Apostolia Maria Tsimberidou

Filip Janku

P577

2016-04-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1037280299

http://www.w3.org/2001/XMLSchema#string

P698

27085994

http://www.w3.org/2001/XMLSchema#string

P921

bevacizumab

phase I clinical trial

Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer.

about

P2860

P2860

Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P921